# Study Of Diabetic Nephropathy With Atrasentan

Study · id `cardio:ct-nct01858532` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01858532](<https://clinicaltrials.gov/study/NCT01858532>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01858532

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 5107 participants.

## Technical summary

Registry record NCT01858532. Randomized; quadruple masking; primary purpose treatment. Start 2013-05-17 (actual); primary completion 2018-03-29 (actual). Results posted on 2019-04-24.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 5107 participants (enrolled count; ClinicalTrials.gov record NCT01858532, source copy `cardio:ctgov-nct01858532-2019-04-24`, retrieved 2026-10-26)
- Started: 2013-05-17 (actual) (ClinicalTrials.gov record NCT01858532, source copy `cardio:ctgov-nct01858532-2019-04-24`, retrieved 2026-10-26)
- Primary completion: 2018-03-29 (actual) (ClinicalTrials.gov record NCT01858532, source copy `cardio:ctgov-nct01858532-2019-04-24`, retrieved 2026-10-26)
- Completion: 2018-03-29 (actual) (ClinicalTrials.gov record NCT01858532, source copy `cardio:ctgov-nct01858532-2019-04-24`, retrieved 2026-10-26)
- Results first posted: 2019-04-24 (ClinicalTrials.gov record NCT01858532, source copy `cardio:ctgov-nct01858532-2019-04-24`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01858532-2019-04-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study Of Diabetic Nephropathy With Atrasentan
- Acronym: SONAR
- Condition: Diabetic Nephropathy
- Intervention (Drug): Atrasentan
- Intervention (Drug): Placebo
- Lead sponsor: AbbVie
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: AbbVie (`cardio:org-abbvie`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial (`cardio:pubmed-30995972`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease (`cardio:pubmed-33338269`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial (`cardio:pubmed-34853062`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure (`cardio:pubmed-35772861`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease (`cardio:pubmed-37657768`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Sex differences in response to the endothelin receptor antagonist atrasentan in individuals with type 2 diabetes and chronic kidney disease: a post hoc analysis of the SONAR trial (`cardio:pubmed-39661119`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c0ec7c207dfd2d184ba029961bffa9aa51499d83180d617839e2d5fbb11fbc31
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
